º´¿ë±Ý±â: µÎ °³ ÀÌ»óÀÇ ¾à¹°À» °°ÀÌ Åõ¿©ÇßÀ» ¶§ ¿¹»óÇÏÁö ¸øÇÑ ÀÌ»ó¹ÝÀÀÀÌ ³ªÅ¸³ª°Å³ª Ä¡·áÈ¿°úÀÇ »ó½ÇÀ» ÃÊ·¡ÇÏ´Â ¾à¹°.
  
°Ë»ö°á°ú: ÃÑ 3°³ Áß 1 - 3

Ƽ»çºê¸®ÁÖ(³ªÅ»¸®ÁÖ¸¿) 15mLÀÇ º´¿ë±Ý±â¿¡ ÇØ´çµÇ´Â Á¦Ç°

Á¦Ç°¸í¡ã¼ººÐ¸íÁÖ¼ººÐÄÚµåÇ¥ÁØÄÚµåÆÇ¸Å»ç°í½Ã¹øÈ£Àû¿ëÀÏ
ŲÅÚ·¹½ºÁÖ(º£µ¹¸®ÁÖ¸¿)_(0.3g/1º´)vedolizumab641301BIJ696300351Çѱ¹´ÙÄÉ´ÙÁ¦¾à(ÁÖ)2025008620251223
ŲÅÚ·¹½ºÇÁ¸®Çʵå½Ã¸°ÁöÁÖ(º£µ¹¸®ÁÖ¸¿)_(0.108g/0.68mL)vedolizumab641302BIJ696300691Çѱ¹´ÙÄÉ´ÙÁ¦¾à(ÁÖ)2025008620251223
ŲÅÚ·¹½ºÇÁ¸®ÇÊµåÆæÁÖ(º£µ¹¸®ÁÖ¸¿)_(0.108g/0.68mL)vedolizumab641302BIJ696300681Çѱ¹´ÙÄÉ´ÙÁ¦¾à(ÁÖ)2025008620251223